Navigation Links
Thermage Announces Second Quarter 2008 Financial Results
Date:8/11/2008

d uncertainties, which may cause Thermage's actual results to differ materially from the statements contained herein including but not limited to market acceptance and demand of current and future products among physicians and patients, our ability to successfully integrate the operations of Reliant and realize synergies, the potential impact of general economic conditions on the demand for our products, risks inherent with third-party supply and distribution networks, risks inherent to future sales growth, and the ability to execute proposed initiatives. Further information on potential risk factors that could affect Thermage's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2007, its Form 10-Q for the quarter ended March 31, 2008 and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Thermage undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Thermage, Inc.

NON-GAAP RECONCILIATION OF

NET INCOME PER SHARE

(unaudited)

Range of Estimates

From To

2008 GAAP diluted net income per share (a) $0.00 $0.03

Stock-based compensation (b) 0.18 0.18

2008 Non-GAAP diluted net income per share (a) $0.18 $0.21

(a) Reflects weighted average outstanding used in calculating diluted net

income per share of 26 million.

(b) Represents the Company's estimate of stock-based compensation

charges, net of ta
'/>"/>

SOURCE Thermage, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Thermage, Inc. to Present at the Maxim Group Growth Conference
2. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
3. Thermage Announces Third Quarter Financial Results
4. Thermage, Inc. Appoints John F. Glenn as Chief Financial Officer
5. Thermage, Inc. Announces Fourth Quarter 2007 Results Release Date and Conference Call
6. Thermage Announces Fourth Quarter and Full Year 2007 Financial Results
7. Thermage, Inc. Announces Initial Shipments of Cellulite Product
8. Thermage, Inc. Announces First Quarter 2008 Results Release Date and Conference Call
9. Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting
10. Thermage, Inc. to Present at the Bank of America 2008 Healthcare Conference
11. Thermage and Reliant Technologies to Join Forces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) ... September, where issues related to claims involving the pain ... Pennsylvania, Bernstein Liebhard LLP reports. , According to ... website, the meeting is scheduled to take place on ... latest of several Tylenol conferences that have taken place ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many ... suppliers carefully, Top10BestSEOHosting.com is here to announce that ... hosting suppliers in 2014. , JustHost ( http://www.justhost.com/track/seohosts ... top-of-the-line shared hosting plan. The company’s approach to ... is affordable, accessible and powerful enough for anyone ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on ... gives members access to thousands of professionally designed tattoo ... aims to help both people who plan on getting ... looking for inspiration in creating one of a kind ... by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . ...
(Date:9/1/2014)... CA (PRWEB) September 01, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... The US FDA announced on August 28, that specific ... recalled (Class I) as the device may reverse ... DePuy Synthes Craniomaxillofacial (CMF) Distraction System is an implant ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3
... molecular mechanisms associated with the development and progression of ... The research, published by Cell Press in the January ... may lead to development of future strategies for treatment ... are derived from migratory neural crest cells that give ...
... January 5, 2008 Scientists from the Gladstone ... discovered that a certain type of collagen, collagen VI, ... widely thought to cause Alzheimer,s disease (AD). While the ... established, before this study it was unknown that collagen ...
... Oral-B Partner with Operation Smile to See the Difference, ... From January through March 2009, Crest and Oral-B are encouraging people ... own smile while also making a difference in children,s smiles worldwide. ... see the difference in their smile. People can also ...
... of infamous psychological obedience study in 1960s , , MONDAY, ... as willing to follow orders to hurt others as they ... , In a replication of one of the most famous ... give what they believed were increasingly painful electric shocks to ...
... Disability healthcare reform will be the subject of ... Disability (NCD) on Tuesday, January 13, 2009, from 3:00 ... held at the Chaparral Suites Resort, 5001 N. Scottsdale ... public. The forum will explore the relationship between health ...
... retinal cell gets infected with the common cytomegalovirus, contiguous ... may provide clues to better treatment of this potentially ... provide new insight into the larger issue of how ... a disease process such as diabetes, said Dr. Sally ...
Cached Medicine News:Health News:New insight into aggressive childhood cancer 2Health News:Collagen VI may help protect the brain against Alzheimer's disease 2Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 2Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 3Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 4Health News:Researcher Finds Most Will Inflict Pain on Others If Prodded 2Health News:Researcher Finds Most Will Inflict Pain on Others If Prodded 3Health News:Disability Healthcare Policy Forum to Be Held in Scottsdale, Arizona 2Health News:Cell death from cytomegalovirus may bring new life to treatment of retinal disease 2
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... A report released,today by The Cornucopia Institute ... formula are seriously endangering the health of,some formula-fed ... Human Breast Milk in the,Laboratory, details research questioning ... produced in laboratories and extracted from,algae and fungus, ...
... on study results demonstrating survival advantage ... months when added to standard therapy, -- First study ... BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: PHRM ) ... positive opinion to recommend approval of Thalidomide,Pharmion(R) for use in ...
Cached Medicine Technology:Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 2Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6
2.5mm...
... 12 bevel tip; silicone sleeve ... is opposite curve, Designed for ... Sleeve acts as stop & ... chance of trauma to the ...
Stab incision blades color coded for simple and accurate identification...
Formed 12.0mm from bend to tip; radius is 12.5 mm;, Curved sharp cutting edge requires less pressure to cut the capsule, reducing stress to zonules. 1.5mm long x .75 mm wide...
Medicine Products: